Cybin Inc.

Cybin Inc.

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days -- Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 -LOS ANGELES & TORONTO, May 09, 2022--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) (NYSE American:CYBN... Read More...

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

TORONTO, April 21, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced that it has partnered with Clinilabs Drug Development Corporation ("Clinilabs"), a global, full-service contract research organiza... Read More...

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

- Delivery of CYB004 via inhalation showed significant advantages over intravenously administered dimethyltryptamine ("IV DMT") in preclinical studies --- Rapid onset, longer duration of action and similar low variability achieved with single inhalation of CYB004 compared with IV DMT –- Inhaled CYB004 demonstrated more than 40% improved b... Read More...

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

TORONTO, March 31, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging... Read More...

Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

-- IND-enabling safety pharmacology and toxicology studies completed in multiple species under GLP guidelines -- On track to submit IND to U.S. FDA in Q2 2022 for expected initiation of Phase 1/2a trial in mid-2022 --TORONTO, March 29, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceu... Read More...

Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

TORONTO, March 24, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", reports that its Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting p... Read More...

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leads Out in Psychedelic-Based Therapeutics Space

NEW YORK, March 07, 2022 -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announces the availability of a broadcast titled, “Psychedelic Therapies Offer Hope for Mental Health.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/JeGwq Th... Read More...

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

-Enrollment expected to begin in early 2022 - TORONTO, January 11, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", today announced that an Institutional Review Board ("IRB") has approved a Company-sponsored feasibility study us... Read More...

Cybin Announces Additional Adelia Milestone Achievement

TORONTO, January 06, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved the milestone identified as Year ... Read More...

Cybin Provides 2021 Year End Summary

TORONTO, December 22, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to provide a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the Company for... Read More...

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

TORONTO, December 08, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to announce that it has confirmed a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency ("MHRA... Read More...

Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights

- Company to host conference call at 4:30pm EST today –TORONTO, November 15, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today reported unaudited financial results for its second quarter ended September 30... Read More...

Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

TORONTO, November 09, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM" today announced that it will report financial results for its second quarter of fiscal 2021 ended September 30, 2021 on Monday, November 15,... Read More...

Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health

Comparative CYB003 pre-clinical data on the Company’s deuterated psilocybin analog may have wide-reaching implications for the treatment of Major Depressive Disorder ("MDD") and Alcohol Use Disorder ("AUD") with less patient variability, faster onset of action, shorter duration of effect and improved brain penetrationTORONTO, November 08,... Read More...

Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development

Promotion of Certain Members of Management Team and Engagement with a Capital Markets Communications FirmTORONTO, October 01, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce: the addition of Dr. Ami... Read More...

Cybin Announces Election of Theresa Firestone as Director, Results of Shareholders’ Meeting and Adoption of Shareholder Rights Plan

TORONTO, August 16, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Theresa Firestone has been elected to its board of directors at the Company’s annual and special meeting of shareholders held... Read More...

Cybin to Commence Trading on the NYSE American on August 5

TORONTO, August 04, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its common shares will open for trading on the NYSE American LLC stock exchange ("NYSE American") on August 5, 2021, under the symbol "CYBN... Read More...

Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, August 03, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB: CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced over... Read More...

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, July 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pricing of its previously announced overnight market... Read More...

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

TORONTO, June 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved certain earn-out milestones for the period ... Read More...

Cybin Announces CDN$20 Million Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, Jan. 18, 2021 - Cybin Inc. (NEO: CYBN) ("Cybin" or the "Company"), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. ("... Read More...

Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition

Cybin Inc. (NEO:CYBN) ("Cybin" or the "Company"), a life sciences company focused on psychedelic therapeutics, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved the earn-out milestones for the period commencing November 15, 2020, as contemplated by the terms of a contrib... Read More...

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

HIGHLIGHTSUsing Kernel’s technology, Cybin will be able to quantify brain activity in real time during psychedelic experiences. The absence of this data has been a limitation in the progression of new molecules targeting neurological disorders.Kernel’s technology opens new frontier in psychedelic therapeutics by acquiring longitudinal bra... Read More...

CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth

Cybin to host conference call today, December 7, 2020, at 5:00 p.m. ETTransaction adds extensive intellectual property portfolio and product pipeline to potentially diversify Cybin’s programs and includes multiple additional indications.Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic ... Read More...